Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pigmentation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Pigmentation. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2013-001633-41 Sponsor Protocol Number: SONIA2 Start Date*: 2013-09-17
    Sponsor Name:University of Liverpool (UniLiv)
    Full Title: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria ...
    Medical condition: Alkaptonuria (AKU) - a serious, autosomal recessive, multisystem disorder.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10001689 Alkaptonuria PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004355-37 Sponsor Protocol Number: B5301001 Start Date*: 2013-06-04
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING
    Medical condition: Hypertrophic skin scarring
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002418-11 Sponsor Protocol Number: RH01913 Start Date*: 2013-08-12
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining
    Medical condition: Tooth discolouration (a labelled undesirable effect of Corsodyl 0.2% mouthwash)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10044032 Tooth discolouration PT
    14.1 10021881 - Infections and infestations 10018292 Gingivitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-004538-32 Sponsor Protocol Number: LIMTOP-I Start Date*: 2012-04-04
    Sponsor Name:Moberg Derma
    Full Title: A double-blind, randomized, multi-centre, vehicle-controlled study of efficacy and safety of a new topical formulation with imiquimod (Limtop) applied 1,3 or 7 times weekly during 2 x 2 weeks treat...
    Medical condition: 5-20 clinically confirmed, palpable or visible (grade I or II according to modified Olsen score), nonhyperkeratotic, nonhypertrophic, AK lesions located within a contiguous (25 - 100 cm²) area on t...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020343-13 Sponsor Protocol Number: ESTEVE-SIGM-106 Start Date*: 2010-06-21
    Sponsor Name:Laboratorios del Dr Esteve S.A
    Full Title: A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young health...
    Medical condition: Pain
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033371 Pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001374-34 Sponsor Protocol Number: 6630-0450-01 Start Date*: 2014-06-11
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG
    Full Title: A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing pro...
    Medical condition: healthy volunteers; intended indication is the treatment of acute wounds such as abrasions, cuts, scratches, laceration, blistering burns and sunburns
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002583-80 Sponsor Protocol Number: 38814 Start Date*: 2013-09-06
    Sponsor Name:Department of Dermatology, Bispebjerg University Hospital
    Full Title: Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety study
    Medical condition: Actinic Keratoses
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004524-36 Sponsor Protocol Number: FESB-DE-310 Start Date*: 2006-10-24
    Sponsor Name:Novartis Consumer Health SA
    Full Title: A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induc...
    Medical condition: Relief of pain and erythema associated with superficial sunburn
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042496 Sunburn PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002678-19 Sponsor Protocol Number: SP148MP201 Start Date*: 2018-03-20
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study
    Medical condition: Metal induced contact dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000490-20 Sponsor Protocol Number: Galderma-Metvix Start Date*: 2018-02-08
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: Evaluation of efficacy, safety and patient¿s satisfaction of daylight photodynamic therapy (DL-PDT) in the treatment of actinic keratosis on the face and scalp and related field cancerization carri...
    Medical condition: actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10064266 Skin hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002202-18 Sponsor Protocol Number: INT 07/07 Start Date*: 2008-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS
    Medical condition: Patients treated for the first time with radiotherapy to the residual breast after quadrantectomy for proven non-metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014982 HLGT
    9.1 10052164 LLT
    9.1 10038604 SOC
    9.1 10006289 HLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000956-42 Sponsor Protocol Number: VRX-RET-E22-304 Start Date*: 2006-09-20
    Sponsor Name:Valeant Pharmaceuticals, North America
    Full Title: A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)
    Medical condition: Adult epilepsy patients with partial-onset seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001489-41 Sponsor Protocol Number: P00003466 Start Date*: 2018-07-02
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease
    Medical condition: Dyskeratosis congenita / telomere disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000945-15 Sponsor Protocol Number: TAS-120-203 Start Date*: 2021-07-28
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma
    Medical condition: Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10077056 Urothelial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000362-38 Sponsor Protocol Number: BBW-11 Start Date*: 2012-06-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Superficial partial-thickness (grade 2a) burn wounds
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006802 Burns second degree PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002328-18 Sponsor Protocol Number: BP40657 Start Date*: 2018-12-19
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUS...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PL (Completed) HU (Completed) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004067-28 Sponsor Protocol Number: MO43576 Start Date*: 2021-12-07
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB F...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) FI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2017-002460-41 Sponsor Protocol Number: TBRU-dS-BA-PIIb Start Date*: 2018-10-29
    Sponsor Name:CUTISS AG
    Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th...
    Medical condition: Adults and adolescents with partial deep dermal and full thickness burns
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002461-21 Sponsor Protocol Number: TBRU-dS-BC-PIIb Start Date*: 2018-10-29
    Sponsor Name:CUTISS AG
    Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th...
    Medical condition: Children with partial deep dermal and full thickness burns
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022777-34 Sponsor Protocol Number: RTG113413 Start Date*: 2011-02-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905).
    Medical condition: Epilepsy - partial-onset seizures with or without secondary generalisation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) ES (Prematurely Ended) BG (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 26 01:25:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA